Analysis of covariates associated with asparaginase hypersensitivity
| Covariate . | % Asparaginase allergy* . | Univariate P value . | Multivariate P value† . |
|---|---|---|---|
| Protocol (% of cases) | Total XV: 204 (41.0%) | 2.1 × 10−51 | 2.3 × 10−46 |
| Total XIIIA: 50 (32.5%) | |||
| POG 9906: 53 (23.9%) | |||
| Total XVI: 38 (14.0%) | |||
| COG AALL0232: 244 (11.3%) | |||
| Combined: 589 (17.8%) | |||
| Asparaginase preparation‡ (% of cases) | E coli asparaginase: 307 (35.1%) | 2.1 × 10−50 | 7.2 × 10−45 |
| PEGylated E coli asparaginase: 282 (11.6%) | |||
| Gender (% of cases) | Male: 351 (18.9%) | .06 | .04 |
| Female: 238 (16.4%) | |||
| Age (<10, ≥10) | <10: 314 (20.3%) | 3.3 × 10−4 | .11 |
| (% of cases) | ≥10: 273 (15.5%) | ||
| Ancestry§ (% of cases) | African: 51 (20.1%) | 2.1 × 10−4 | .07 |
| European: 385 (19.7%) | |||
| Hispanic: 102 (14.1%) | |||
| Other: 40 (13.2%) | |||
| Asian: 4 (7.5%) | |||
| ALL lineage|| (% of cases) | B-lineage¶: 263 (33.8%) | 5.3 × 10−4 | .003 |
| T-lineage¶: 27 (18.8%) |
| Covariate . | % Asparaginase allergy* . | Univariate P value . | Multivariate P value† . |
|---|---|---|---|
| Protocol (% of cases) | Total XV: 204 (41.0%) | 2.1 × 10−51 | 2.3 × 10−46 |
| Total XIIIA: 50 (32.5%) | |||
| POG 9906: 53 (23.9%) | |||
| Total XVI: 38 (14.0%) | |||
| COG AALL0232: 244 (11.3%) | |||
| Combined: 589 (17.8%) | |||
| Asparaginase preparation‡ (% of cases) | E coli asparaginase: 307 (35.1%) | 2.1 × 10−50 | 7.2 × 10−45 |
| PEGylated E coli asparaginase: 282 (11.6%) | |||
| Gender (% of cases) | Male: 351 (18.9%) | .06 | .04 |
| Female: 238 (16.4%) | |||
| Age (<10, ≥10) | <10: 314 (20.3%) | 3.3 × 10−4 | .11 |
| (% of cases) | ≥10: 273 (15.5%) | ||
| Ancestry§ (% of cases) | African: 51 (20.1%) | 2.1 × 10−4 | .07 |
| European: 385 (19.7%) | |||
| Hispanic: 102 (14.1%) | |||
| Other: 40 (13.2%) | |||
| Asian: 4 (7.5%) | |||
| ALL lineage|| (% of cases) | B-lineage¶: 263 (33.8%) | 5.3 × 10−4 | .003 |
| T-lineage¶: 27 (18.8%) |
Percent asparaginase allergy refers to the percentage of cases within each category that had asparaginase hypersensitivity reactions.
Multivariate P values refer to the association of each covariate with treatment arm, gender, age, ancestry, and ALL lineage included in the model as categorical covariates.
Asparaginase preparation was confounded with protocol, therefore the multivariate P value for asparaginase was estimated by removing protocol from the model.
Ancestry was estimated using genotyped SNPs.
ALL lineage refers to the ALL immunophenotype.
Univariate P value for ALL lineage was calculated only for the SJCRH cohort because T-ALL patients were only enrolled within those protocols; all COG protocols were B-lineage ALL only; see also supplemental Figure 1.